NLRP3 and metabolic dysfunction-associated steatohepatitis: Supporting this pathomechanism, inhibition of the PAMP responsive NLRP3 inflammasome by the small molecule MCC950 reduced the severity of liver inflammation and fibrosis in NASH models.